Computer-aided Detection (CAD) Market Size & Forecast
The Computer-aided Detection (CAD) Market is projected to reach $1.56 billion by 2031, at a CAGR of 7.4% from 2024 to 2031. Computer-aided detection is utilized in the categorization and identification of benign and malignant lesions. It assists vascular physicians in deciding the most effective treatments for patients with cardiovascular diseases using techniques such as mammography, ultrasound, and MRI. CAD technologies enhance radiologists' ability to detect and distinguish between normal and abnormal (cancerous) tissues. Furthermore, CAD is used to detect and diagnose various cancers, including breast, lung, and liver cancers. It reduces the chances of false negative/positive results in disease diagnosis.
The growth of the CAD market is driven by the rising prevalence of chronic diseases, increasing awareness regarding the importance of early cancer diagnosis, increasing investments and funding for cancer research, and rising healthcare expenditures. However, the high costs of CAD solutions restrain the growth of this market.
Additionally, the growing acceptance of CAD among radiologists, the increase in cancer screening programs, and advancements in CAD solutions, such as the integration of Artificial Intelligence (AI) and Machine Learning (ML), are expected to generate market growth opportunities. However, the lack of technical expertise required for using CAD systems is a significant challenge impacting the market's growth.
Increasing Awareness Regarding the Importance of Early Cancer Diagnosis Driving Market Growth
In recent years, the growing prevalence of cancer and the associated mortalities have raised awareness about the importance of early cancer diagnosis. A significant number of cancer cases are diagnosed in advanced stages, primarily due to a lack of awareness. Numerous organizations are actively undertaking initiatives such as awareness programs and campaigns to promote early cancer detection. These initiatives highlight the risks associated with cancer and emphasize the significance of timely and regular cancer diagnoses. Some of the initiatives are as follows:
-
In November 2023, Apollo Cancer Centre (India) launched a breast cancer diagnosis program to provide rapid and accurate breast cancer diagnoses, highlighting the importance of early detection in selecting the right treatments for a higher survival rate and improving patients' quality of life.
- In October 2023, the American Liver Foundation (U.S.) conducted a free liver cancer conference for patients and their families to encourage them to take control over their health and learn more about everything from treatment options, new research advances, and clinical trials to awareness and dealing with medical side effects.
- In October 2023, the Illinois Department of Public Health (IDPH) (U.S.) launched the National Breast Cancer Awareness Program to highlight the importance of the early detection of breast cancer.
- In September 2023, the International Association for the Study of Lung Cancer (IASLC) (U.S.) launched the National Lung Cancer Early Detection Program to help identify lung cancer early through Low-dose Computed Tomography (LDCT) lung cancer screening, focusing on people with a family history of lung cancer along with those with a history of frequent smoking.
Thus, increasing awareness regarding the importance of early cancer diagnosis is boosting the adoption of CAD solutions.
![Computer-aided Detection (CAD) Market Computer-aided Detection (CAD) Market](https://www.meticulousresearch.com/public/website_images/Computer-aided-Detection-(CAD)-Market.webp)
Click here to: Get Free Sample Pages of this Report
Increase in Cancer Screening Programs to Generate Market Growth Opportunities
Government and healthcare organizations around the world are launching cancer screening programs and campaigns to raise awareness and reduce the global burden of cancer. For instance:
-
In September 2023, the Government of New Brunswick (Canada) launched a lung cancer screening program to screen high-risk patients. Under this program, the Government of New Brunswick has invested $3.4 million to support lung cancer screening.
- In June 2023, Breast Cancer Canada collaborated with AstraZeneca (U.K.) and Illumina (U.S.) to provide breast cancer screening and detection research grants. Under this collaboration, nearly $151,381 will be provided to Canadian research teams in funding, facilitating the use of precision diagnostics and AI technology to advance breast cancer detection and screening.
- In June 2023, INVENTIVA S.A. (France) and Echosens SA (France) launched an initiative to increase awareness regarding Non-Alcoholic Steatohepatitis (NASH) and other diseases, including liver cancer, and improve access to screening for at-risk patients.
- The U.K.’s NHS Breast Screening Programme extends invitations for screening to all women between the ages of 50 and 70 every three years. According to the National Health Service (NHS) Breast Screening Programme, in 2021, 2.20 million women aged over 45 underwent screening tests, compared to 1.97 million in 2020.
This increase in cancer screening programs is expected to boost the adoption of CAD solutions, generating market growth opportunities.
Key Findings in the Computer-aided Detection (CAD) Market Study:
The Oncology Segment to Account for the Largest Market Share in 2024
Based on application, in 2024, the oncology segment is expected to account for the largest share of the computer-aided detection market. The segment’s large share is attributed to the increasing prevalence of breast cancer and the increase in breast cancer detection and awareness campaigns. Breast cancer ranks among the most prevalent cancers affecting women globally. According to the World Health Organization (WHO), 2.3 million breast cancer cases were recorded globally in 2020, and this number is expected to reach 3 million by 2040. The rising incidence of breast cancer has led to a rapid increase in the adoption of innovative technologies, such as CAD, aimed at enhancing breast cancer detection through a combination of various modalities.
The Mammography Segment to Account for the Largest Market Share in 2024
Based on imaging modality, in 2024, the mammography segment is expected to account for the largest share of the computer-aided detection market. The segment’s large share is attributed to the introduction of advanced mammography systems with cutting-edge technologies and the growing use of computer-aided detection in multispecialty hospitals. CAD technology improves patient outcomes by increasing the precision of mammography readings and decreasing the risk of false positives. Furthermore, the growth in breast cancer screening programs in developed countries also contributes to the segment’s large share.
The Hospitals & Clinics Segment to Account for the Largest Market Share in 2024
Based on end user, in 2024, the hospitals & clinics segment is expected to account for the largest share of the computer-aided detection market. The segment’s large share is attributed to the rising prevalence of cancer, the growing number of hospitals and clinics, the availability of highly skilled professionals in hospitals and clinics, the high purchasing power of hospitals, and the increasing patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgical procedures.
Asia-Pacific to be the Fastest-growing Regional Market
Based on geography, Asia-Pacific is expected to record the highest CAGR during the forecast period. The growth of this regional market is driven by rising breast cancer cases, growing awareness regarding the importance of early diagnosis and detection of cancer, cardiovascular diseases, and neurological disorders, the increase in cancer screening programs, the expansion of the healthcare sector, and increasing government investments and initiatives supporting cancer research.
Computer-aided Detection (CAD) Market: Key Players
This report includes a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them in the last three to four years. The key players profiled in the computer-aided detection market report are Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), GE HealthCare Technologies Inc. (U.S.), Hologic, Inc. (U.S.), FUJIFILM Holdings Corporation (Japan), EDDA Technology, Inc. (U.S.), Canon Medical Systems Corporation (Japan), Riverain Technologies (U.S.), Median Technologies (France), Agfa-Gevaert NV (Belgium), iCAD Inc. (U.S.), CureMetrix, Inc. (U.S.), and THERAPIXEL (France).
Computer-aided Detection (CAD) Market Report Summary :
Particulars
|
Details
|
No. of Pages
|
260
|
Format
|
PDF
|
Forecast Period
|
2024–2031
|
Base Year
|
2023
|
CAGR
|
7.4%
|
Market Size (Value)
|
$1.56 Billion
|
Segments Covered
|
By Application
- Oncology
- Breast Cancer
- Lung Cancer
- Liver Cancer
- Colon/Rectal Cancer
- Prostate Cancer
- Bone Cancer
- Other Cancer Types
- Cardiology
- Other Applications
(Note: Other applications include neurology, diabetic retinopathy, and tuberculosis.)
By Imaging Modality
- Mammography
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Ultrasound Imaging
- Other Imaging Modalities
(Note: Other imaging modalities include X-ray imaging and endoscopy.)
By End User
- Hospitals & Clinics
- Diagnostic Imaging Centers
- Ambulatory Care and Surgery Centers
|
Countries Covered
|
North America (U.S., Canada), Europe (Germany, France, Italy, U.K., Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
|
Companies Profiled
|
Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), GE HealthCare Technologies Inc. (U.S.), Hologic, Inc. (U.S.), FUJIFILM Holdings Corporation (Japan), EDDA Technology, Inc. (U.S.), Canon Medical Systems Corporation (Japan), Riverain Technologies (U.S.), Median Technologies (France), Agfa-Gevaert NV (Belgium), iCAD Inc. (U.S.), CureMetrix, Inc. (U.S.), and THERAPIXEL (France)
|
Key Questions Answered in the Report: